Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies
10 févr. 2014 07h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 10, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Three papers published in Health Physics, Volume 106, Number 1 (January 2014)
...
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA
23 janv. 2014 10h52 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jan 23, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Fiscal Year 2013 Financial Results
23 déc. 2013 08h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 23, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Files Application for New Patent on AEOL 10150
05 déc. 2013 11h14 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 5, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Filing covers synthesis, formulation and pharmaceutical composition
...
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation
29 oct. 2013 08h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Oct 29, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Optimal dose of AEOL 10150 improved survival by four times over untreated...
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome
17 sept. 2013 13h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 17, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
BARDA exercise options valued at $6.0 million effective September 16, 2013...
Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent Surrogate for Soman and Sarin Gas
11 sept. 2013 12h20 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 11, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
National Institutes of Health - National Institute of Neurological...
Aeolus Announces Third Quarter Fiscal Year 2013 Financial Results
14 août 2013 16h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus' AEOL 10150 Significantly Improves Survival From Nitrogen Mustard Exposure to Skin in Animals
02 juil. 2013 08h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 2, 2013) - Aeolus Pharmaceuticals (OTCQB: AOLS)
Data presented at 6th Annual NIH CounterACT Network Research Symposium
...
Aeolus' AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
26 juin 2013 14h02 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 26, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data presented at 7th Annual NIH CounterACT Network Research...